Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment
- PMID: 33111132
- PMCID: PMC7581383
- DOI: 10.1016/j.bbih.2020.100163
Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment
Abstract
Background: Cognitive manifestations associated with the severity of a novel coronavirus (COVID-19) infection are unknown. An early detection of neuropsychological manifestations could modify the risk of subsequent irreversible impairment and further neurocognitive decline.
Methods: In our single-center cohort study, we included all consecutive adult patients, aged between 20 and 60 years old with confirmed COVID-19 infection. Neuropsychological assessment was performed by the same trained neuropsychologist from April, 22nd through June 16th, 2020. Patients with previous known cognitive impairment, any central nervous system or psychiatric disease were excluded. Demographic, clinical, pharmacological and laboratory data were extracted from medical records.
Results: Thirty-five patients met inclusion criteria and were included in the study. Patients presenting headache, anosmia, dysgeusia, diarrhea and those who required oxygen therapy had lower scores in memory, attention and executive function subtests as compared to asymptomatic patients. Patients with headache and clinical hypoxia scored lower in the global Cognitive Index (P = 0.002, P = 0.010). A T score lower than 30 was observed in memory domains, attention and semantic fluency (2 [5.7%]) in working memory and mental flexibility (3 [8.6%]) and in phonetic fluency (4 [11.4%]). Higher scores in anxiety and depression (P = 0.047, P = 0.008) were found in patients with cognitive complaints.
Conclusions: In our cohort of COVID-19 patients neurologic manifestations were frequent, including cognitive impairment. Neurological symptoms during infection, diarrhea and oxygen therapy were risk factors for neurocognitive impairment. Cognitive complaints were associated with anxiety and depression.
Keywords: COVID-19; Cognitive impairment; Coronavirus; Neurological manifestations; Neuropsychology.
© 2020 The Author(s).
Conflict of interest statement
The authors have no affiliation with any organization with a direct or indirect financial interest in the subject matter discussed in the manuscript.
References
-
- Arentz M., Yim E., Klaff L., Lokhandwala S., Riedo F.X., Chong M., Lee M. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. Jama. 2020;323(16):1612–1614. https://doi:10.1001/jama.2020.4326 - DOI - PMC - PubMed
-
- Areza-Fegyveres R., Kairalla R.A., Carvalho C.R., Nitrini R. Cognition and chronic hypoxia in pulmonary diseases. Dementia & Neuropsychol. 2010;4(1):14–22. https://doi:10.1590/S1980-57642010DN40100003 - DOI - PMC - PubMed
-
- Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Yu T. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. https://doi:10.1016/S0140-6736(20)30211-7 - DOI - PMC - PubMed
-
- Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Du B. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708–1720. https://doi:10.1056/NEJMoa2002032 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous